The Role of Interleukin Pathways in Reducing the Clinical and Economic Burden of Psoriatic Disease: Updates for Specialty Pharmacists

The Role of Interleukin Pathways in Reducing the Clinical and Economic Burden of Psoriatic Disease: Updates for Specialty Pharmacists 

On-Demand 1.5-hour Accredited Webcast

Faculty Presenters

Jamie L. McConaha, PharmD, NCTTP, BCACP, CDCES
Associate Professor of Pharmacy Practice
Duquesne University School of Pharmacy
Pittsburgh, Pennsylvania

Renee Baiano, PharmD, CSP
Clinical Program Manager
AllianceRx Walgreens Prime
Pittsburgh, Pennsylvania
 
Program Description
The complexity of psoriatic arthritis (PsA) progression and associated comorbidities presents both a clinical and economic burden on patients and health care systems. Patients with PsA often struggle with psychosocial challenges due to burden of their diagnosis and unmet treatment needs. Appropriate treatment selection and early initiation may curtail the progression of the disease and reduce long-term consequences, such as joint damage and functional disability. The interleukin pathways have been identified as major contributors to the development and progression of both psoriasis and PsA and have led to the development of several effective targeted therapies. Specialty and managed care pharmacists should be aware of PsA treatment guidelines and management considerations for the diverse therapeutic landscape. The overall management of PsA requires a dedicated team of health care providers and a patient-centered treatment approach. This activity will equip specialty pharmacists and managed care professionals with the most up-to-date research regarding the evolving treatment of landscape of PsA and provide considerations to improve outcomes for patients.

Target Audience: Managed care and specialty pharmacists
Type of Activity: Application
Release date: May 18, 2021
Expiration date: May 18, 2022
Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives
At the completion of this activity, participants will be able to:

• Explain the epidemiology, pathophysiology, clinical presentation, and importance of early diagnosis of psoriatic arthritis
• Examine the mechanism of action, efficacy, safety, and adverse effects of current and emerging interleukin inhibitors for psoriatic arthritis
• Identify the role of the managed care professional and specialty pharmacist in minimizing the burden of psoriatic arthritis

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-21-205-H01-P. The activity is available for CE credit through May 18, 2022.


Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
 

---

Disclosures

Jamie L. McConaha, PharmD, NCTTP, BCACP, CDCES, and Renee Baiano, PharmD, CSP, have no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Farah Rose Namissa, PharmD, BCPS; Michelle C. Carlson, PharmD, RPh; Kelly McCormick; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.

An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms